BioMérieux Unveils SMARTBIOME, a DNA-Based Solution to Combat Food Spoilage
French company bioMérieux announced on February 18, 2026, the launch of SMARTBIOME, a solution aimed at the agri-food industry to better understand and prevent microbiological spoilage. This platform combines DNA sequencing, bioinformatics, and microbiological expertise to enhance product quality and reduce food loss.
The Challenge of Microbiological Spoilage in the Food Industry
Microbiological spoilage is a significant challenge for the food industry. Microorganisms such as Pseudomonas bacteria, spore-forming bacteria, or certain molds can degrade fresh and processed products, leading to waste and economic losses. According to a scientific review published in Nature Reviews Microbiology (Snyder, Martin & Wiedmann, 2024), 15 to 20% of food produced worldwide is discarded, partly due to microbial deterioration phenomena. SMARTBIOME aims to precisely identify these spoilage floras and understand their origins.
Integrating High-Resolution Genomic Sequencing and Data Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The solution combines high-resolution genomic sequencing, data analysis, and a specialized knowledge base to transform complex microbiological data into actionable information. Developed in collaboration with Brazilian company Neoprospecta, acquired by bioMérieux in January 2025, it enables the tracking of microbiological evolution over time, anticipation of contaminations, and adjustment of production processes. SMARTBIOME is already available in Europe, North America, and Latin America.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
